GlycoMimetics Inc (GLYC)
0.242
+0.03
(+11.78%)
USD |
NASDAQ |
Dec 24, 16:00
GlycoMimetics Cash from Investing (Quarterly): 0.00 for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -16.16M |
| Arbutus Biopharma Corp | -11.99M |
| Revance Therapeutics Inc | 23.29M |
| FibroGen Inc | 0.755M |
| Cidara Therapeutics Inc | -0.106M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.994M |
| Free Cash Flow | -35.02M |
| Free Cash Flow Per Share (Quarterly) | -0.124 |
| Free Cash Flow Yield | -224.5% |